On the morning of Jan. 25, following Zhang Lao out as usual, near 10 a.m. the nurse teacher asked Zhang Lao if he could give an extra number to an out-of-town patient, and Zhang Lao agreed, and generally the teacher would agree to such requests, “it’s not easy to come from out of town,” the teacher always thinks of the patient. The patient who came in was about 40 years old and was accompanied by a family member who looked very much like him, two brothers. The patient’s face reminded me of the medical term “sallow face”, either liver or kidney disease, I guessed. Sure enough, the patient had a history of hepatitis B for 18 years and alcoholism for 15 years. He had been diagnosed with liver cancer for 4 months and had jaundice, ascites, portal vein thrombosis, and black stools. The family said that the patient was very irritable, could not sleep at night, and sometimes babbled nonsense. The patient kept his head down, spoke in a low voice, was very thin, only his abdomen was bulging, and his eyes glowed unusually bright when he raised his head occasionally. From the results of the laboratory tests, it appeared that this patient had signs of hepatic coma. This was a patient with advanced hepatocellular carcinoma. The family pleaded hard, we came from Xinjiang, the local doctor said there is nothing to do, begged the old doctor to think of a solution, the brother is only 41 years old, there are old people on the top and 2 minor children on the bottom. I have been practicing medicine for 26 years, and I know that there is nothing anyone can do when a patient with liver cancer reaches this stage. He prescribed a medicine to relieve the symptoms, mainly for the irritability caused by liver coma and the severe abdominal distension caused by ascites. At the same time, Zhang instructed the family to make sure to do tests related to hepatitis B. The patient’s brother said that he had already checked and that the family members were all hepatitis B patients. After the patient left, Elder Zhang was a little excited, “We oncologists can’t just treat these patients who already have cancer, the focus of treatment should be shifted forward, like this patient, it is impossible for him to get better himself, the key is how to prevent his family members from getting liver cancer, there is no special medicine for liver cancer yet, we can only cut it off from the source.” Zhang’s words made me think for a long time. Liver cancer, also known as hepatocellular carcinoma, is the third most common type of tumor in the world, with more than 1 million new patients diagnosed worldwide each year. It is the third most common type of tumor in the world, with more than 1 million new patients diagnosed worldwide and more than 620,000 deaths annually. As for the causes of liver cancer, a recently published survey of patients admitted to the M. D. An-derson Cancer Center in the United States indicates that 24% of liver cancers are due to hepatitis C virus infection, nearly 10% are due to hepatitis B virus infection, about 41% are related to daily alcohol abuse, and another 25% have unknown causes. 50-60% of patients with hepatocellular carcinoma have clinically diagnosable hepatic sclerosis. Because of this, although the incidence of liver cancer in Europe and the United States is still low and liver cancer is a rare disease depending on the number of patients, scholars in Europe and the United States are now calling for a substantial increase in the incidence of liver cancer in Europe and the United States in the next 5 years because of the increasing prevalence of hepatitis C in these countries, which is one of the most important known risk factors for liver cancer. Compared to Europe and the United States, Southeast Asia and the sub-Saharan region, including China and Japan, have the highest incidence of liver cancer in the world due to the high prevalence of hepatitis B and C. The annual number of deaths from this disease accounts for about 50% of the total number of deaths worldwide. The incidence of liver cancer in China is expected to increase because of the custom of drinking strong alcohol in some regions of the country and the unhygienic food (moldy grains contain aflatoxin, a powerful liver cancer-causing substance) and drinking water in some areas. The statistical report shows that the incidence of liver cancer in China is more than 10 times higher than that in western countries, so it is of great social and clinical importance to pay attention to the progress of research on liver cancer treatment drugs. Xinjiang is a region with a high incidence of hepatitis in China, and the local alcoholism culture is very serious, which aggravates the development of hepatitis towards cirrhosis and the incidence of liver cancer is among the highest in China. The average survival rate of liver cancer patients is less than 50% in 6 months, 24% in 1 year and only 5% in 5 years after diagnosis. With such a poor prognosis, the incidence of liver cancer is closely related to the prevalence of hepatitis B and C virus infection, for which there are very limited therapeutic options available, with no officially approved effective treatment drugs to date. In view of the fact that China is a region with high incidence of hepatocellular carcinoma, and that the incidence of hepatocellular carcinoma in China is still on the rise due to the wide range of hepatitis B and C virus infections, it is incumbent upon the pharmaceutical industry in China to pay attention to the research progress of hepatocellular carcinoma treatment drugs. The most commonly used drugs for liver cancer treatment are adriamycin and fluorouracil, but these drugs have low efficiency and no significant life-prolonging effect on the treatment of liver cancer, especially unresectable liver cancer patients. Chinese medicine can reduce the symptoms of liver cancer patients and prolong their survival to a certain extent, but the cure rate is also very low. As we can see, no tumor has a clear cause like liver cancer, which also provides us with opportunities for prevention. Since 1990, our country has been forcing newborns to receive hepatitis B vaccine, which is expected to significantly reduce the incidence of liver cancer, vigorously controlling alcohol can reduce the incidence of alcoholic liver, and controlling moldy food can limit human exposure to aflatoxin. If these three factors can be adequately controlled, the reduction of liver cancer incidence will not be an empty phrase!